US federal health officials outline pre-approval groundwork for psychedelic medicines
Federal Health Officials Outline Pre-Approval Roadmap for Psychedelic Medicines
Officials from HHS, the FDA, the VA and ARPA-H described at The Psychedelic Healthcare Forum on Oct. 15 how an April executive order has reshaped federal preparation for psychedelic medicines. HHS Deputy General Counsel Matt Zorn said the order does not change statutory or regulatory standards, while the VA has designated 10 medical centres as Phase 1Phase 1The first studies of a drug in people, usually in small numbers, looking mainly at safety and dose.Open the glossary lead sites and estimated around 100,000 veterans would qualify for psychedelic-assisted therapy immediately upon approval. The FDAFDAThe Food and Drug Administration, the United States regulator of medicines, medical devices and food.Open the glossary's Dr Valentina Mantua said the agency oversees approximately 433 Investigational New Drug applications and has already requested REMS proposals from developers, and ARPA-H's Dr Al Bugazia cited cardiotoxicity and QTc prolongation risks, the lack of a domestic GMP manufacturer and a DEA manufacturing quota of just over 200 grams as obstacles for ibogaine research.
Key facts
- Kind of item
- Guidance and consultations
- Compounds
- Psilocybin, MDMA, Ibogaine
- Regulator
- FDA (United States)
- Jurisdiction
- United States
- Trial phase
- Phase 1
- Participants
- around 100,000 veterans (as written in the text)
- Source
- Lucid News (lucid.news)
- Published
- Original
- Read it at lucid.news
How this summary was made
The summary was written by an AI model from the linked source, and a model scored the item against this site's editorial criteria. The facts above come from the item's topics and from identifiers written out in the stored text. Anything not found there is left out, so a missing row means not stated, not no. Read the original before relying on any detail. Editorial method
Source: Lucid News · lucid.news
Connected to
- Kind of item
- Guidance and consultations
- Compounds
- PsilocybinMDMAIbogaine
- Regulator
- FDA (United States)
- Jurisdiction
- United States